Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Scientists identify more aggressive chemotherapy treatment for childhood brain cancer

Scientists identify more aggressive chemotherapy treatment for childhood brain cancer

Scientists led by Newcastle University have been able to identify the group of children needing more intensive, aggressive chemotherapy treatment for the most common form of brain cancer.

The chromosome signature they have identified in medulloblastoma could allow medics to adapt treatment so that each child is targeted individually, improving the 60% survival rate for high-risk patients.

The study’s findings, published today in The Lancet Oncology, also shows that many youngsters with medulloblastoma could avoid unnecessary doses of chemotherapy and radiotherapy with less toxic side effects.

While others, who have the most serious form of the disease, may be targeted with more intensive chemotherapy. Currently all patients receive the same treatment.

Personalised treatment

Professor Steve Clifford, Director of the Northern Institute for Cancer Research, Newcastle University, UK, led the European study with Dr Edward Schwalbe, from Northumbria University.

Professor Clifford said: “Our findings provide a new blueprint for the personalisation of treatment in medulloblastoma so that all children are not given the same intensity of therapy.

“This study shows that low-risk patients may receive kinder treatments aimed at reducing toxicity and side effects, while targeting more intensive treatments to the high-risk patients who need it most.

“Medulloblastoma is the most common malignant childhood brain tumour and it is important that we have improved outcomes for patients with this disease.

“Through a greater understanding of brain tumours we hope to increase the cure rate but critically, for those children who survive, we want to make sure their quality of life is good after treatment.”

Scientists at Newcastle University’s Wolfson Childhood Cancer Research Centre worked with Northumbria University and European collaborators to examine the molecular pathology of the cancer.

The study is part of the largest completed clinical trial of medulloblastoma undertaken across Europe and it is hoped that it will lead to significantly improved outcomes for patients in the future.

Clinical groups

Experts identified that children with the cancer can be split into two clinical groups – about half of which are low-risk with close to 100% survival, while the other half are high-risk, with 60% survival.

The study analysed data from the PNET4 clinical trial of standard-risk medulloblastoma, which ran from 2001-2006, and was partly funded by Cancer Research UK.

The standard-risk patients involved in the cohort were children with no recognised risk factors for the disease and who would be expected to have a survival rate of around 80% after five years.

Working with the University of Bonn in Germany, the Newcastle and Northumbria team identified recurrent patterns of chromosome gains and losses in medulloblastoma tumours.

The team found a chromosome signature that identifies a group of patients with 100% survival rates, and a high-risk group with just 60% survival.

Dr Ed Schwalbe, Senior Lecturer in Bioinformatics and Biostatistics at Northumbria University, said: “In this study, we identified an easily testable chromosome signature that predicts excellent outcomes for children with medulloblastoma. Importantly, we also show that this signature works as expected in an independent set of patients.

“Looking forward, we hope that children whose tumours have this signature could be treated less aggressively, reducing the life-long side effects of the gruelling treatments, while maintaining a cure.”

Medulloblastoma is the most common high grade childhood tumour, accounting for 15%-20% of all childhood brain tumours.

Current treatment for the cancer is surgery to remove the tumour, followed by radiotherapy and an intensive course of chemotherapy.

Researchers are now working with the European trial group to implement the findings of this study clinically as part of forthcoming trials to adapt therapy in the future.

Case study

Schoolboy Olly McKenna was diagnosed with medulloblastoma less than a year ago and has battled back to health.

The 12-year-old, from Bill Quay, Gateshead, had surgery for nine hours to remove his aggressive tumour and underwent months of gruelling radiotherapy and chemotherapy.

Today his parents Jason and Jill have welcomed the research being undertaken in the North East into this form of brain cancer.

Jill, 44, a superintendent radiographer, said: “It is incredibly important that as much research as possible is done into medulloblastoma so that patients receive the best treatment options.

“Each child currently diagnosed with the condition is given the same treatment and this level of toxicity makes the youngsters very ill – for parents it’s awful watching their child go through that.

“To know that research has identified that therapy should be tailored to each individual child is fantastic as it will mean that children will not be given toxic treatment unnecessarily.

“The most important thing is that children have as few side effects as possible so that they can continue to have a good quality of life during and after treatment.”

Source:

https://www.ncl.ac.uk/press/articles/latest/2018/11/medulloblastomaresearch/

Tagged with:

About author

Related Articles